Management of neuroendocrine carcinomas of the pancreas (WHO G3): A tailored approach between proliferation and morphology

Stefano Crippa, Stefano Partelli, Giulio Belfiori, Marco Palucci, Francesca Muffatti, Olga Adamenko, Luca Cardinali, Claudio Doglioni, Giuseppe Zamboni, Massimo Falconi

Research output: Contribution to journalReview article

Abstract

Neuroendocrine carcinomas (NEC) of the pancreas are defined by a mitotic count > 20 mitoses/10 high power fields and/or Ki67 index > 20%, and included all the tumors previously classified as poorly differentiated endocrine carcinomas. These latter are aggressive malignancies with a high propensity for distant metastases and poor prognosis, and they can be further divided into small-and large-cell subtypes. However in the NEC category are included also neuroendocrine tumors with a well differentiated morphology but ki67 index > 20%. This category is associated with better prognosis and does not significantly respond to cisplatin-based chemotherapy, which represents the gold standard therapeutic approach for poorly differentiated NEC. In this review, the differences between well differentiated and poorly differentiated NEC are discussed considering both pathology, imaging features, treatment and prognostic implications. Diagnostic and therapeutic flowcharts are proposed. The need for a revision of current classification system is stressed being well differentiated NEC a more indolent disease compared to poorly differentiated tumors.

Original languageEnglish
Pages (from-to)9944-9953
Number of pages10
JournalWorld Journal of Gastroenterology
Volume22
Issue number45
DOIs
Publication statusPublished - Dec 7 2016

Fingerprint

Neuroendocrine Carcinoma
Pancreas
Software Design
Neoplasms
Neuroendocrine Tumors
Mitosis
Cisplatin
Therapeutics
Pathology
Neoplasm Metastasis
Carcinoma
Drug Therapy

Keywords

  • Chemotherapy
  • Metastases
  • Morphology
  • Neuroendocrine carcinomas
  • Pancreatic neuroendocrine tumors
  • Prognosis
  • Proliferation
  • Surgery

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Management of neuroendocrine carcinomas of the pancreas (WHO G3) : A tailored approach between proliferation and morphology. / Crippa, Stefano; Partelli, Stefano; Belfiori, Giulio; Palucci, Marco; Muffatti, Francesca; Adamenko, Olga; Cardinali, Luca; Doglioni, Claudio; Zamboni, Giuseppe; Falconi, Massimo.

In: World Journal of Gastroenterology, Vol. 22, No. 45, 07.12.2016, p. 9944-9953.

Research output: Contribution to journalReview article

Crippa, Stefano ; Partelli, Stefano ; Belfiori, Giulio ; Palucci, Marco ; Muffatti, Francesca ; Adamenko, Olga ; Cardinali, Luca ; Doglioni, Claudio ; Zamboni, Giuseppe ; Falconi, Massimo. / Management of neuroendocrine carcinomas of the pancreas (WHO G3) : A tailored approach between proliferation and morphology. In: World Journal of Gastroenterology. 2016 ; Vol. 22, No. 45. pp. 9944-9953.
@article{c9f29e6f5e9647fc935bdd87e853931d,
title = "Management of neuroendocrine carcinomas of the pancreas (WHO G3): A tailored approach between proliferation and morphology",
abstract = "Neuroendocrine carcinomas (NEC) of the pancreas are defined by a mitotic count > 20 mitoses/10 high power fields and/or Ki67 index > 20{\%}, and included all the tumors previously classified as poorly differentiated endocrine carcinomas. These latter are aggressive malignancies with a high propensity for distant metastases and poor prognosis, and they can be further divided into small-and large-cell subtypes. However in the NEC category are included also neuroendocrine tumors with a well differentiated morphology but ki67 index > 20{\%}. This category is associated with better prognosis and does not significantly respond to cisplatin-based chemotherapy, which represents the gold standard therapeutic approach for poorly differentiated NEC. In this review, the differences between well differentiated and poorly differentiated NEC are discussed considering both pathology, imaging features, treatment and prognostic implications. Diagnostic and therapeutic flowcharts are proposed. The need for a revision of current classification system is stressed being well differentiated NEC a more indolent disease compared to poorly differentiated tumors.",
keywords = "Chemotherapy, Metastases, Morphology, Neuroendocrine carcinomas, Pancreatic neuroendocrine tumors, Prognosis, Proliferation, Surgery",
author = "Stefano Crippa and Stefano Partelli and Giulio Belfiori and Marco Palucci and Francesca Muffatti and Olga Adamenko and Luca Cardinali and Claudio Doglioni and Giuseppe Zamboni and Massimo Falconi",
year = "2016",
month = "12",
day = "7",
doi = "10.3748/wjg.v22.i45.9944",
language = "English",
volume = "22",
pages = "9944--9953",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "45",

}

TY - JOUR

T1 - Management of neuroendocrine carcinomas of the pancreas (WHO G3)

T2 - A tailored approach between proliferation and morphology

AU - Crippa, Stefano

AU - Partelli, Stefano

AU - Belfiori, Giulio

AU - Palucci, Marco

AU - Muffatti, Francesca

AU - Adamenko, Olga

AU - Cardinali, Luca

AU - Doglioni, Claudio

AU - Zamboni, Giuseppe

AU - Falconi, Massimo

PY - 2016/12/7

Y1 - 2016/12/7

N2 - Neuroendocrine carcinomas (NEC) of the pancreas are defined by a mitotic count > 20 mitoses/10 high power fields and/or Ki67 index > 20%, and included all the tumors previously classified as poorly differentiated endocrine carcinomas. These latter are aggressive malignancies with a high propensity for distant metastases and poor prognosis, and they can be further divided into small-and large-cell subtypes. However in the NEC category are included also neuroendocrine tumors with a well differentiated morphology but ki67 index > 20%. This category is associated with better prognosis and does not significantly respond to cisplatin-based chemotherapy, which represents the gold standard therapeutic approach for poorly differentiated NEC. In this review, the differences between well differentiated and poorly differentiated NEC are discussed considering both pathology, imaging features, treatment and prognostic implications. Diagnostic and therapeutic flowcharts are proposed. The need for a revision of current classification system is stressed being well differentiated NEC a more indolent disease compared to poorly differentiated tumors.

AB - Neuroendocrine carcinomas (NEC) of the pancreas are defined by a mitotic count > 20 mitoses/10 high power fields and/or Ki67 index > 20%, and included all the tumors previously classified as poorly differentiated endocrine carcinomas. These latter are aggressive malignancies with a high propensity for distant metastases and poor prognosis, and they can be further divided into small-and large-cell subtypes. However in the NEC category are included also neuroendocrine tumors with a well differentiated morphology but ki67 index > 20%. This category is associated with better prognosis and does not significantly respond to cisplatin-based chemotherapy, which represents the gold standard therapeutic approach for poorly differentiated NEC. In this review, the differences between well differentiated and poorly differentiated NEC are discussed considering both pathology, imaging features, treatment and prognostic implications. Diagnostic and therapeutic flowcharts are proposed. The need for a revision of current classification system is stressed being well differentiated NEC a more indolent disease compared to poorly differentiated tumors.

KW - Chemotherapy

KW - Metastases

KW - Morphology

KW - Neuroendocrine carcinomas

KW - Pancreatic neuroendocrine tumors

KW - Prognosis

KW - Proliferation

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=85003031556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85003031556&partnerID=8YFLogxK

U2 - 10.3748/wjg.v22.i45.9944

DO - 10.3748/wjg.v22.i45.9944

M3 - Review article

AN - SCOPUS:85003031556

VL - 22

SP - 9944

EP - 9953

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 45

ER -